Mark Kidd
University of the Witwatersrand
Survival analysisDeep learningEpigenomeCancerInternal medicineMetabolomePathologyOncologyGene expressionArtificial intelligenceProgenitorOmicsTranscriptomeRetrospective cohort studyMolecular diagnosticsCognitive scienceProspective cohort studySystematic reviewIn vivoLung cancerKi-67Neuroendocrine cellPancreasProgressive diseaseNeuroendocrine tumorsEntinostatMalignancyMEDLINESunitinibLiver transplantationEverolimusModalitiesContext (language use)Molecular pathogenesisReady to usePredictive biomarkerNeuroendocrine tumourPlasma samplesTumor tissuePrecision oncologyCancer researchArtificial neural networkBioinformaticsClinical decision support systemMedicineBiomarker (medicine)Chromogranin ASomatostatin receptorCell cultureBiologyMeta-analysisReproducibility
7Publications
5H-index
198Citations
Publications 7
Newest
#1Mark KiddH-Index: 5
#2Alexandra KitzH-Index: 2
Last. Irvin M Modlin (Yale University)H-Index: 3
view all 4 authors...
BACKGROUND: The NETest is a multi-gene assay comprising 51 circulating neuroendocrine tumor specific transcripts. The quotient of the 51-gene assay is based upon an ensemble of machine learning algorithms. Eight cancer hallmarks or "omes" (apoptome, epigenome, growth factor signalome, metabolome, proliferome, plurome, secretome SSTRome) represent 29 genes. The NETest is an accurate diagnostic (>90%) but its prognostic utility has not been assessed. In this study, we describe expansion of the NET...
5 CitationsSource
#1Irvin M Modlin (Yale University)H-Index: 3
#2Mark KiddH-Index: 5
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 4 authors...
2 CitationsSource
#1Ashley K. CliftH-Index: 13
#2Mark KiddH-Index: 5
Last. Andrea FrillingH-Index: 13
view all 8 authors...
: The traditionally promulgated perspectives of neuroendocrine neoplasms as rare, indolent tumours are blunt and have been outdated for the last two decades. Clear increments in their incidence over the past decades render them increasingly clinically relevant, and at initial diagnosis many present with nodal and/or distant metastases (notably hepatic). The molecular pathogenesis of these tumours is increasingly yet incompletely understood. Those arising from the small bowel or pancreas typicall...
20 CitationsSource
#1Anna MalczewskaH-Index: 12
#2Mark KiddH-Index: 5
Last. Irvin M Modlin (Yale University)H-Index: 3
view all 7 authors...
BACKGROUND: Management of bronchopulmonary neuroendocrine neoplasia (NEN; pulmonary carcinoids [PCs], small-cell lung cancer [SCLC], and large cell neuroendocrine carcinoma) is hampered by the paucity of biomarkers. Chromogranin A (CgA), the default neuroendocrine tumor biomarker, has undergone wide assessment in gastroenteropancreatic neuroendocrine tumors. OBJECTIVES: To evaluate CgA in lung NEN, define its clinical utility as a biomarker, assess its diagnostic, prognostic, and predictive effi...
9 CitationsSource
#1Mark KiddH-Index: 5
#2Ignat DrozdovH-Index: 37
Last. Irvin M Modlin (Yale University)H-Index: 3
view all 9 authors...
BACKGROUND: Multigene-based PCR tests are time-consuming and limiting aspects of the protocol include increased risk of operator-based variation. In addition, such protocols are complex to transfer and reproduce between laboratories. AIMS: Evaluate the clinical utility of a pre-spotted PCR plate (PSP) for a novel multigene (n = 51) blood-based gene expression diagnostic assay for neuroendocrine tumors (NETs). METHODS: A pilot study (n = 44; 8 controls and 36 NETs) was undertaken to compare CQ, n...
7 CitationsSource
#1Mariano J. Alvarez (Columbia University)H-Index: 27
#2Prem S. Subramaniam (Columbia University)H-Index: 30
Last. Andrea CalifanoH-Index: 76
view all 58 authors...
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins that mechanistically regulate tumor cell state, as assessed from systematic drug perturbation assays. We validated the approach on a cohort of 212 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a rare ma...
86 CitationsSource
#1Andrea Frilling (Imperial College London)H-Index: 19
#2Göran Åkerström (University of the Witwatersrand)H-Index: 83
Last. I. M. Modlin (University of the Witwatersrand)H-Index: 1
view all 7 authors...
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) represent a heterogenous group of tumors arising from a variety of neuroendocrine cell types. The incidence and prevalence of GEPNENs have markedly increased over the last three decades. Symptoms are often absent in early disease, or vague and nonspecific even in advanced disease. Delayed diagnosis is thus common. Chromogranin A is the most commonly used biomarker but has limitations as does the proliferative marker Ki-67%, which is ofte...
101 CitationsSource